FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Assessment of Patient-Reported Outcome Measures in Patients Undergoing Bowel Preparation With Mannitol for Colonoscopy: The SATISFACTION Study. PMID 40786127 · JGH Open · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Arterial stiffness moderates the link between NfL and cognition: The IGNITE study. PMID 40775489 · Alzheimers Dement · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial. PMID 40769686 · Lancet Haematol · 2025-Aug 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| A multimodal sexual dysfunction intervention versus enhanced usual care for survivors of haematopoietic stem-cell transplantation: a single-centre, open-label, randomised clinical trial. PMID 40769685 · Lancet Haematol · 2025-Aug The study is an oncology-related randomized trial in humans with original results, but it does not meet two key inclusion criteria: 1) It is not explicitly a Phase III/IIIb or Phase II/III trial (phase is not specified, and it is a single-centre study unlikely to be definitive Phase III); 2) The intervention is non-pharmacological (no drug-containing intervention). The primary endpoint is a patient-reported outcome (sexual satisfaction score) at a fixed time point, not a time-to-event endpoint like OS or PFS, and no Kaplan-Meier or HR analysis is reported. Therefore, it is ineligible for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial. PMID 40769684 · Lancet Haematol · 2025-Aug The trial is an oncology Phase III randomized trial with drug interventions, but the primary endpoint is MRD negativity, a categorical response endpoint, not a time-to-event endpoint (e.g., OS, PFS, DFS). No time-to-event outcome or analysis (Kaplan-Meier, HR) is reported in the abstract. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of an online mindfulness program (MindOnLine) to reduce fear of recurrence in people living with-and beyond-breast, prostate or colorectal cancer: a randomized controlled trial. PMID 40756964 · EClinicalMedicine · 2025-Aug The record describes a randomized trial in oncology patients, but it does not meet the eligibility criteria: the trial phase is not specified, the intervention is a non-drug psychological program, and the endpoints are not time-to-event outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Improvement in Patient-Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO. PMID 40755069 · Eur J Neurol · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The Evolving Landscape of Systemic Immunotherapy for Bacillus Calmette-Guérin-naïve High-risk Non-muscle-invasive Bladder Cancer: At the Edge of a Tsunami? PMID 40752989 · Eur Urol Oncol · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Management of Chemotherapy-induced Oral Mucositis in Gastrointestinal Malignancies: Evidence From Randomized Controlled Trails. PMID 40750413 · Anticancer Res · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: A single-arm, phase 2 trial from China. PMID 40748918 · PLoS Med · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Low Testosterone Level and Mortality Risk in Patients With Prostate Cancer: A Post-Randomization Analysis. PMID 40747769 · Cancer Med · 2025-Aug The record is a post-randomization analysis from a randomized trial. It reports time-to-event outcomes (PCSM and ACM) but does not establish a Phase III/IIIb or Phase II/III trial design or a drug-containing intervention as required. The analysis is subgroup-focused by comorbidity status. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation. PMID 40740293 · EClinicalMedicine · 2025-Aug The study is a target trial emulation of a non-randomized comparison of antiretroviral regimens in HIV patients, focusing on clinical outcomes including cancer. It is not a randomized controlled trial for an oncologic indication with a standard oncologic time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial. PMID 40736519 · Ann Dermatol · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The COMFORT Trial: A Randomised Control Trial Comparing Group-Based COMpassion-FOcused Therapy Techniques and Breathing Pattern ReTraining With Treatment as Usual on the Psychological Functioning of Patients Diagnosed With Cancer Recurrence. PMID 40736172 · Cancer Med · 2025-Aug The study is a randomized, original-result oncology trial in humans, but it fails two key eligibility criteria: 1) the primary endpoint is distress (a patient-reported quality-of-life measure), not a time-to-event efficacy endpoint like OS or PFS, and 2) the intervention is purely psychological/behavioral, with no drug component. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Combined Topical Lidocaine and Tetracaine Cream for Facial Fractional Laser Resurfacing Compared With Its Reference Product in Chinese Adults: A Multicenter, Randomized, Double-Blind Phase 3 Study. PMID 40735955 · J Cosmet Dermatol · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Aztreonam-avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE). PMID 40727714 · JAC Antimicrob Resist · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial. PMID 40727012 · EClinicalMedicine · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma. PMID 40714516 · ESMO Open · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer. PMID 40714513 · ESMO Open · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Multicenter Single-Blind Randomized Controlled Trial of the Romiplostim Biosimilar. PMID 40708707 · EJHaem · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 study. PMID 40708530 · Expert Opin Biol Ther · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Belatacept Pharmacokinetic Analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to Clinical Outcomes and Compared With Reported BENEFIT and BENEFIT-EXT Pharmacokinetic Analysis. PMID 40704545 · Clin Transplant · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2. PMID 40693847 · NEJM Evid · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The effect of abaloparatide on the proximal femur in men with osteoporosis assessed by three-dimensional dual-energy X-ray absorptiometry. PMID 40692760 · JBMR Plus · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Study protocol for a randomized controlled effectiveness trial of THRIVE group and peer coaching to promote suicide recovery in crisis stabilization centers. PMID 40688062 · Contemp Clin Trials Commun · 2025-Aug 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Safety and effectiveness of the Walk 'n Watch structured, progressive exercise protocol delivered by physical therapists for inpatient stroke rehabilitation in Canada: a phase 3, multisite, pragmatic, stepped-wedge, cluster-randomised controlled trial. PMID 40683274 · Lancet Neurol · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Reply to letter comments on: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine). PMID 40682909 · ESMO Open · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Clinical utility of photodynamic diagnosis with 5-aminolevulinic acid hydrochloride for detecting carcinoma in situ independent of urine cytology classification. PMID 40680915 · Photodiagnosis Photodyn Ther · 2025-Aug This is a human oncology Phase III trial with original results. However, it is excluded because it is not randomized, the intervention is a diagnostic technique (photodynamic diagnosis) rather than a drug-containing therapy, and the primary endpoint is diagnostic accuracy, not a time-to-event efficacy outcome. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clearing the air: Empowering high-risk adults with digital tools for smoking cessation and lung cancer screening adoption. PMID 40669310 · Lung Cancer · 2025-Aug The study meets criteria for being an original, randomized, human oncology trial, but it is excluded because it is not a Phase III/IIIb or Phase II/III trial, lacks a primary time-to-event efficacy endpoint, and does not have a drug-containing intervention as defined by the protocol (nicotine replacement is considered part of a behavioral/digital intervention bundle, not a standalone drug intervention for cancer treatment). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients. PMID 40669094 · ESMO Open · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Letter to the Editor Re: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomized, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine). PMID 40669093 · ESMO Open · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Endotypes of Pseudomonas aeruginosa Infection in Bronchiectasis Are Associated with Inhaled Antibiotic Response: Results from Two Randomized, Double-Blind, Placebo-controlled Phase III Trials (ORBIT 3 and ORBIT 4). PMID 40664229 · Am J Respir Crit Care Med · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-term efficacy and safety of arimoclomol in Niemann-Pick disease type C: Final results of the phase 2/3 NPC-002 48-month open-label extension trial. PMID 40663813 · Mol Genet Metab · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial. PMID 40652943 · Lancet Oncol · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Preliminary data on the oncological safety of autologous fat transfer (AFT) for total breast reconstruction from the BREAST trial. PMID 40652913 · J Plast Reconstr Aesthet Surg · 2025-Aug 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis. PMID 40651932 · Eur Urol Oncol · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Nurse AMIE randomized controlled trial to address symptom management among rural advanced Cancer patients: Addressing malignancies in everyday life. PMID 40651555 · Contemp Clin Trials · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. PMID 40651490 · Lancet Respir Med · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis. PMID 40650731 · Clin Drug Investig · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Designing a response-over-continuous-intervention (ROCI) randomised trial: Implementation in the Phase 2C part (duration ranging) of the PARADIGM4TB trial. PMID 40645367 · Contemp Clin Trials · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema. PMID 40637159 · J Comp Eff Res · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of Mavacamten on Cardiac Magnetic Resonance Features in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy. PMID 40632050 · JACC Asia · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial. PMID 40630018 · Alcohol Clin Exp Res (Hoboken) · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial. PMID 40628965 · Nat Med · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia: treating mitochondrial dysfunction with anaplerosis. PMID 40616902 · EBioMedicine · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel. PMID 40616865 · Int J Gynecol Cancer · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Indirect Treatment Comparison of Long-Acting Injectable Cabotegravir as Pre-exposure Prophylaxis When Compared with no Pre-exposure Prophylaxis for HIV Prevention. PMID 40616767 · Infect Dis Ther · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| "A 10-years follow-up of Photodynamic Therapy for nodular basal cell carcinoma: a randomized comparing the effectiveness of Aminolevulinic acid-PDT, Methyl aminolevulinate-PDT, and surgery". PMID 40614840 · Photodiagnosis Photodyn Ther · 2025-Aug While the study is a randomized oncology trial with time-to-event endpoints, it fails two critical eligibility criteria: 1) The intervention (Photodynamic Therapy) is not considered a 'drug-containing intervention' as defined by the cohort (requiring cytotoxic, hormonal, or targeted agents). 2) The phase of the trial is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E-4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial. PMID 40614747 · Lancet HIV · 2025-Aug 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Impact of Machine Learning Mortality Risk Prediction on Clinician Prognostic Accuracy and Decision Support: A Randomized Vignette Study. PMID 40613383 · Med Decis Making · 2025-Aug Study is a randomized vignette survey evaluating a machine learning tool's impact on clinician prognostic accuracy in mNSCLC. It is not a clinical trial of a drug intervention with a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |